Role of advanced glycation end products in hypertension and atherosclerosis: therapeutic implications

Sudesh Vasdev1, Vicki Gill, Pawan Singal

  • 1Discipline of Medicine, Faculty of Medicine, Room H-4310, Health Sciences Centre, Memorial University of Newfoundland, St. John's, NF, A1B 3V6, Canada. svasdev@mun.ca

Insights

Insulin resistance contributes to vascular diseases like hypertension and atherosclerosis by increasing advanced glycation end products (AGEs). Therapies targeting insulin resistance and AGEs show promise in treating these conditions.

Area of Science:

  • Cardiovascular Science
  • Metabolic Disease Research
  • Biochemistry

Background:

  • Hypertension and atherosclerosis are leading global causes of mortality.
  • Both vascular diseases share insulin resistance as a common characteristic.
  • Insulin resistance may be influenced by genetic and lifestyle factors.

Purpose of the Study:

  • To explore the role of insulin resistance and advanced glycation end products (AGEs) in hypertension and atherosclerosis.
  • To investigate potential therapeutic strategies targeting AGEs and insulin resistance.

Main Methods:

  • Examined the link between insulin resistance, aldehyde production (glyoxal, methylglyoxal), and AGE formation.
  • Reviewed human and animal studies on AGEs in vascular diseases.
  • Assessed the efficacy of interventions that reduce insulin resistance and AGEs.

Main Results:

  • Insulin resistance leads to aldehyde accumulation, forming AGEs that damage proteins.
  • AGEs contribute to endothelial dysfunction, inflammation, and oxidative stress, hallmarks of hypertension and atherosclerosis.
  • Studies show therapies reducing AGEs and insulin resistance improve vascular health.

Conclusions:

  • Advanced glycation end products (AGEs) play a pathological role in hypertension and atherosclerosis.
  • Therapies including antioxidants, AGE breakers, and lifestyle changes can mitigate these vascular diseases.
  • Targeting insulin resistance and AGEs offers a novel therapeutic approach for cardiovascular conditions.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
287
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
837
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
694
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
867
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.3K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
405